Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Olaszország2/3. fázis

A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence

A legfontosabb adatok

Ki végzi
Centessa Pharmaceuticals UK Limited
Hol
Bologna, Rome és Verona (Olaszország)Mind a 3 helyszín megnézéseMég 7 másik országban, 24 helyszínen
Állapot
Toborzás még nem indult
Fázis
2/3. fázis
Résztvevők
198 fő, tervezett
Kezdés
2026. okt. 1.
Várható befejezés
2028. febr. 1.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. november 13.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with narcolepsy type 1 or type 2 who have strong daytime sleepiness. It compares cleminorexton with placebo, a dummy treatment.

Életkor
18 Years and older
Nem
All sexes
A betegség stádiuma
A doctor diagnosed narcolepsy type 1 (with cataplexy) or type 2 (without cataplexy) within the past 10 years. Average time to fall asleep on a stay-awake test (MWT) must be < 21 minutes. People with type 1 must have ≥ 4 cataplexy episodes (sudden muscle weakness) per week over 14 days. They must fill in a diary on at least 11 of those 14 days.
Korábbi kezelés
People with type 1 must first stop medicines for cataplexy. Medicines for daytime sleepiness must be stopped first, such as stimulants, wake-promoting drugs, sodium oxybate or mixed-salt oxybate. Sleeping pills, including melatonin, are not allowed. Antidepressants and other medicines that affect cataplexy must stop at least 7 days before the sleep diary starts.
Biomarker vagy leletérték
People with type 1 need a positive test for the tissue type HLA DQB1*06:02. This can be from screening or an earlier test. People cannot join if a spinal fluid test showed orexin A > 110 pg/mL, where such a test exists.

A részvétel fő kizáró okai

  • Another condition causing daytime sleepiness, such as untreated sleep apnea or a limb-movement index > 15
  • Serious heart, cancer, nervous system, mental health or other illness
  • Heart rhythm problems on ECG, or QTcF >450 msec in males or > 470 msec in females
  • Blood pressure or pulse outside set limits
  • Pregnancy, breastfeeding, or usual bedtime later than 1:00 AM

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • A physician documented diagnosis of NT1 according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria within the past 10 years from informed consent
  • Positive test result for the human leukocyte antigen (HLA) genotype HLA DQB1*06:02 (either during Screening or based on a documented historical test result)
  • A mean sleep latency on the MWT (average of the first 4 trials) at Baseline of < 21 minutes
  • After washout of medications used for the treatment of cataplexy, must complete self-reported cataplexy questions in the diary for at least 11 days of the 14-day period prior to the Baseline visit and have ≥ 4 partial or complete episodes of cataplexy/week, averaged over 14 consecutive days prior to the Baseline visit
  • A physician documented diagnosis of NT2 according to ICSD-3-TR criteria within the past 10 years from informed consent
  • Mean sleep latency on the MWT (average of the first 4 trials) at Baseline of < 21 minutes

Ki nem vehet részt

  • Use of any medications that could affect the evaluation of cataplexy (including antidepressants) within 7 days before the baseline sleep diary. Participants must have returned to baseline level of cataplexy by the time of the beginning of the cataplexy diary, in the opinion of the investigator. "
  • Use of any medications that could affect the evaluation of EDS (eg, medications that stimulate the central nervous system [CNS])
  • Any medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS): evidence of untreated or inadequately treated moderate-to-severe sleep-disordered breathing and/or periodic limb-movement-arousal index > 15
  • Conditions related to the following: cardiac, malignancy, gastrointestinal, endocrine, neurologic, psychiatric, immunologic, other significant conditions or comorbidities that would make the participant unsuitable to be randomized and/or participate
  • Use of medications for EDS (including wake-promoting agents, stimulants, and sodium oxybate or mixed-salt oxybate). Certain washout periods apply (see Appendix 10.7 for full details)
  • Positive serum pregnancy test at Screening or Baseline, or is a pregnant, lactating/ female participant
  • QT interval using the Fridericia formula (QTcF) >450 msec for males or > 470 msec for females or evidence of clinically significant electrocardiogram (ECG) abnormality (eg, 2nd or 3rd degree atrioventricular block [known history of Mobitz Type I may be considered with approval from the Sponsor or designee], left bundle branch block [LBBB])
  • A cerebrospinal fluid (CSF) orexin A (OXA) > 110 pg/mL (if available)
  • Use of hypnotics (including melatonin)
  • Abnormalities at Screening or Baseline in blood pressure (BP, systolic BP > 140 mm Hg or < 90 mm Hg; diastolic BP > 90 mm Hg or < 50 mm Hg) or pulse rate (> 100 bpm or < 40 bpm)
  • Usual bedtime later than 1:00 AM (01:00)

Helyszínek itt: Olaszország

Még 7 másik országban, 24 helyszínen

  • Azienda Unita Sanitaria Locale Di BolognaBologna, OlaszországToborzás még nem indult
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, OlaszországToborzás még nem indult
  • Centro Ricerche Cliniche di Verona s.r.l.Verona, OlaszországToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

Evaluate the effect of cleminorexton versus placebo on EDS

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared with Placebo in Participants with Central Disorders of Hypersomnolence
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. november 13.